Back to top
more

Zoetis (ZTS)

(Delayed Data from NYSE)

$159.70 USD

159.70
4,849,556

+1.28 (0.81%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $159.76 +0.06 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).

Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.

Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zoetis (ZTS) Q1 Earnings Top Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of 3.15% and 0.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More

by Kinjel Shah

Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.

Why Earnings Season Could Be Great for Zoetis (ZTS)

by Zacks Equity Research

Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Aquestive Therapeutics (AQST) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 210% and 9.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are likely to have driven first-quarter sales.

Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Zoetis (ZTS) closed the most recent trading day at $173.95, moving +0.58% from the previous trading session.

Earnings Preview: Zoetis (ZTS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Zoetis (ZTS) closed at $176.88, marking a +1.42% move from the previous day.

ALPMY or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ALPMY vs. ZTS: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights NIKE, Toyota Motor, ConocoPhillips, PayPal and Zoetis

by Zacks Equity Research

NIKE, Toyota Motor, ConocoPhillips, PayPal and Zoetis are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Q1 Earnings Scorecard and Analyst Reports for NIKE, Toyota Motor & ConocoPhillips

by Sheraz Mian

Today's Research Daily features Q1 earnings season update and new research reports on NIKE, Inc. (NKE), Toyota (TM) and ConocoPhillips (COP).

Zoetis (ZTS) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Zoetis (ZTS) closed at $164.47 in the latest trading session, marking a -1.11% move from the prior day.

The Zacks Analyst Blog Highlights Nike, Salesforce, Zoetis, Archer-Daniels-Midland and Trane Technologies

by Zacks Equity Research

Nike, Salesforce, Zoetis, Archer-Daniels-Midland and Trane Technologies are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Research Reports for Nike, Salesforce & Zoetis

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including NIKE, Inc. (NKE), Salesforce, Inc. (CRM) and Zoetis Inc. (ZTS).

Zoetis (ZTS) Down 6.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

COLL vs. ZTS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

COLL vs. ZTS: Which Stock Is the Better Value Option?

Zoetis' (ZTS) Q4 Earnings in Line With Estimates, Revenues Beat

by Zacks Equity Research

Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.

Zoetis (ZTS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zoetis (ZTS) Matches Q4 Earnings Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of 0% and 1.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

COLL or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

COLL vs. ZTS: Which Stock Is the Better Value Option?

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are expected to have driven sales, partially offset by lower sales of livestock, cattle, poultry and swine products.

Zoetis (ZTS) Stock Moves -0.78%: What You Should Know

by Zacks Equity Research

Zoetis (ZTS) closed the most recent trading day at $160.81, moving -0.78% from the previous trading session.